Bioline RX Ltd (NASDAQ:BLRX) – Equities research analysts at Roth Capital dropped their Q3 2016 earnings per share estimates for shares of Bioline RX in a research report issued on Thursday, according to Zacks Investment Research. Roth Capital analyst J. Pantginis now anticipates that the brokerage will post earnings per share of ($0.09) for the quarter, down from their prior forecast of ($0.08). Roth Capital has a “Buy” rating and a $7.00 price objective on the stock. Roth Capital also issued estimates for Bioline RX’s FY2016 earnings at ($0.33) EPS and FY2017 earnings at ($0.36) EPS.

A number of other brokerages have also issued reports on BLRX. Zacks Investment Research raised shares of Bioline RX from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a report on Wednesday, November 18th. JMP Securities dropped their price objective on shares of Bioline RX from $3.50 to $3.00 and set a “market outperform” rating for the company in a report on Wednesday, March 9th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Bioline RX from $3.50 to $3.00 and set a “market outperform” rating for the company in a report on Wednesday, March 9th. Five research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $3.65.

Bioline RX (NASDAQ:BLRX) opened at 1.01 on Monday. Bioline RX has a 12 month low of $0.85 and a 12 month high of $2.80. The stock’s market cap is $55.19 million. The stock has a 50 day moving average of $1.02 and a 200-day moving average of $1.30.

Bioline RX (NASDAQ:BLRX) last issued its quarterly earnings data on Thursday, March 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.01.

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

12 Month Chart for NASDAQ:BLRX

 

Source: Financial market news

Provision Holding Inc (OTCMKTS:PVHO) is making a highly explosive move up on accelerating volume as the Company continues to put out some big news in recent weeks. PVHO has transformed in recent weeks from illiquid to one of the top most traded stocks on the entire exchange.

2016 has been a big year for PVHO which has been trading on the bb’s for years to little interest from Investors. 1st the WolfofPennyStocks announced it as their new pick spiking the price up to $0.114 highs, this was followed by a significant drop to mid $0.05’s before the stock embarked on the current run which has eclipsed WolfofPennyStocks $0.113 highs.

Provision Holding Inc (OTCMKTS:PVHO) is the leading purveyor of intelligent interactive 3D holographic display technologies, software, and integrated solutions for both commercial and consumer focused applications.

Provision’s 3D holographic display systems represent a revolutionary technology that provides the projection of full color, high-resolution videos into space detached from the screen, without any special glasses. Provision is currently the market leader in true 3D consumer advertising display products being implemented by innovative, consumer-focused companies.

According to filings PVHO did $1.17 million in the 3rd quarter 2015 compared to just $49 thousand for the same quarter in 2014. Provision reported a net profit of $82 thousand for the quarter ended September 30, 2015, compared to a net loss of $321 thousand last year.

Following the Wolf’s promotion PVHO said in a statement that ”The Company is not affiliated with the promotional materials’ author or its affiliated entities or persons. The Company’s recent press releases have reported on and provided disclosure of legitimate and ongoing corporate activity only, and are not part of any promotional activities or campaign,” stated Curt Thornton, CEO of Provision Holding. Provision encourages those interested in the Company to rely solely on information included in its press releases read with its filings and disclosures.

Recently PVHO announced 200 3D Savings Center Kiosks have been successfully installed. These installations represent continued penetration of the New York City and Los Angeles markets for its key retail partner, one of the largest retail drugstore chains in the United States. Provision’s 3D Savings Center Kiosks generate eye-popping, three dimensional, holographic videos and will include exclusive loyalty card information and promotions.

Currently, the kiosks are featuring ads for store brand products. Going forward, the kiosks are expected to provide unique on-site advertising and promotion for a variety of major brands.

According to a recent letter to shareholders PVHO progress in 2015 was initiated in 2014 when they obtained financing from DB Dava and announced that they would begin their initial kiosk rollout to 200 stores and become current in our SEC periodic filings.

                                                   

In May 2015 PVHO announced the completion of Comprehensive Form 10-K to achieve the goal of compliance with SEC regulations. That same month the Company announced Pharmark Ad Sales for Rite Aid. In September PVHO announced shipping first 100 kiosks to Rite Aid. In October they announced a partnership with Fujifilm to install and service kiosks and announced installation of first 150 kiosks. In November PVHO announced quarterly results with $1M in revenues. Further, to kick off the year, in January 2016 PVHO announced the shipment of an additional 250 kiosks for immediate installation.

On February 4 PVHO announced it has issued a total of $4 million, before commissions and expenses, in a private placement financing of 12% Series A Senior Secured Convertible Promissory Notes, convertible into shares of the Company’s common stock at a conversion price of $0.10 per share. Each note purchaser will also receive, for every $1,000 in promissory notes purchased, warrants to purchase 2,000 shares of the Company’s common stock at an exercise price of $0.15 per share for a period of five years after the warrant’s issuance. Radnor Research & Trading Company acted as sole placement agent for the financing.

The financing should assist in the Company’s growth beyond its current installations of approximately 450 3D Savings Center kiosks with a national retail customer. The Company plans to have 1,000 3D Savings Center kiosks installed by the second quarter.

CEO Curt Thornton said “We are pleased to have closed on this round of financing and to have been able to do so at a significant premium to the market, despite the recent broader market volatility. 2016 is a pivotal year in the continued evolution of Provision and the commercialization of our proprietary technology.”

Currently trading at a $9 million market valuation PVHO does have 1.8 million in the treasury and significant aforementioned revenues. However the Company has been on the bb’s for years and has been losing money all along which has resulted in significant debt on the books that is going to have a huge impact on the Company’s future. But PVHO is an exciting story in small caps; the Company is a leading purveyor of intelligent interactive 3D holographic display technologies and the stock has finally broken out on big volume after years of inactivity.

 

Source: Microcap Daily

A ‘buy’ recommendation and a $2 price target bodes well for the clinical-stage specialty pharmaceutical company.

 

RegeneRx Biopharmaceuticals Inc (OTCMKTS:RGRX) shares gained more than 7% on Monday morning, after its prospects were written up by Rodman & Renshaw.

A ‘buy’ recommendation and a $2 price target bodes well for the clinical-stage specialty pharmaceutical company, which is currently evaluating a possible treatment for dry eye syndrome.

Analyst Raghuram Selvaraju says the ‘unmet need’ in dry eye syndrome represents a ‘massive market opportunity’.

Rodman & Renshaw’s recommendation suggests more than 300% upside to the current share price, of 48.2 cents.

Results from a Phase 2b/3 trial, possible coming in the second quarter, present investors in RegeneRx with a potential value-adding trigger and it also pointed to the possibility that data could be released from a separate Phase 3 trial for the treatment of neurotrophic keratitis (NK) during the second quarter as well.

“Safety is critical for dry eye therapeutics, as adverse reactions often lead to treatment discontinuation,” Selvaraju said in a note.

Selvaraju added that compared to Restasis, the only FDA approved treatment available, RegeneRx’s treatment was well tolerated in a prior Phase 2a trial and that could help the drug quickly seize market share if it is approved.

The analyst also emphasised that RegeneRx benefits from licensing arrangements which allows for non-dilutive funding for its trials.

“RegeneRx has a unique licensing setup that we feel should benefit its shareholders.

“All ongoing trials of RGN-259 is sponsored by ReGenTree, a joint venture established by RegeneRx and GtreeBNT. GtreeBNT is responsible for funding all trials and holds a majority stake in the JV.”

The analyst added: “RegeneRx bears no financial risk for the clinical testing of RGN-259 and maintains a low operational cash burn.”

 

Source: Proactive Investors

Cannabis Sativa Inc. (OTCMKTS:CBDS) is one of today’s hottest penny stocks, but with no real reason for the surge, the smart-money thing may be lock in those gains while you can and divert the proceeds to New Global Energy Inc. (OTCMKTS:NGEY)… which has something tangible going for it.

 

Congratulations to owners of Cannabis Sativa Inc. (OTCMKTS:CBDS). CBDS shares are up 43% today following a 280% pop yesterday, proving that the right penny stocks at the right time in the right situation can be like winning the lottery.

Problem: There’s nothing directly behind the advance from CBDS, leaving the stock vulnerable to a pullback once the market realizes Cannabis Sativa is little more than a premise. That’s in complete contrast with a similar company called New Global Energy Inc. (OTCMKTS:NGEY), that’s setting up a mini-empire in the moringa industry… a legal plant that can be utilized as a health food in a variety of ways. Better still, unlike Cannabis Sativa Inc., NGEY is already up and running.

Cannabis Sativa has an “ambition to brand and market the highest quality, legal cannabis products available today – and to innovate the industry-leading products of tomorrow. We foresee a future where the hi brand is synonymous with the highest quality and best value in the cannabis space; a vision we plan to support through aggressive marketing and strategic alliances.”

So what sparked a monster-sized rally from CBDS? Nothing the company did.

Most likely, the rally was kick-started by this report from Marijuana Business Daily suggesting the industry could be worth more than $40 billion by 2020. That was enough not just to send Cannabis Sativa shares higher, but all marijuana stocks higher.

Yet, it can’t be ignored that CBDS is a $34.9 million company that’s generated $12,460 worth of business, and lost $19.4 million in the process.

Like so many other penny stocks, the Cannabis Sativa is about the future – not the present. The rub is, it’s been about the future since 2012. The company, and most of its peers, never seem to make any actual progress towards the proverbial land despite the launch of new product after new product after new product. Calling a spade a spade, too many of these marijuana and cannabinoid companies were started because somebody wanted to turn a hobby into a business, with the proprietors not appreciating that fact that it’s tough to make a business viable.

That may or may not apply to Cannabis Sativa, but so far, it seems to apply.

That’s in sharp contrast to New Global Energy. But what is New Global Energy? First and foremost, it’s a play on moringa.

Moringa , or moringa oleifera to be specific, is a fast-growing tree that produces leaves and seed-pods which contain an amazing amount of nutritional value. On pound-for-pound basis, moringa has 25 times more iron than spinach, ten times more vitamin A than carrots, four times more protein than eggs, and boasts about a dozen more “X times more than” benefits. It’s also rich with antioxidants, minerals like calcium and magnesium, and more. In fact, if the human race had to pick just one plant-based food to survive, moringa would be an ideal choice.

Moringa isn’t just a source of nutrition though. It’s also got medicinal value, being linked to lower cholesterol, lowering of blood sugar, and anti-inflammatory activity.

As for how it’s used/served, it can be dried, turned into powder, made into tea, cooked fresh, and a bunch of other ways.

It’s quickly becoming a big hit within the growing health-minded market too. In October New Global Energy announced it was partnering up with International Sustainability Group — which makes AlgaeUp(tm) bars — to manufacture and distribute MoringaUP(tm) Protein Bars. Since then, the company announced it had met with representatives from aquaculture feed supplier EWOS, which was recently acquired by none other than Cargill. The purpose of the meeting was discuss several exploratory projects subsidiary Aqua Farming Tech is working on, including the use of moringa as part of a fish feed.

Where NGEY truly stands out among penny stocks, however, is that it’s already up and running, generating revenue, and primed for growth.

The new moringa crop acreage at its Mecca, California farm could annually produce as much as $9 million worth of moringa. The company’s website has already noted that the 6000 moringa trees its planted in Thermal, California plus another 10,000 trees at its Mecca farm plus 20 acres of moringa tree in addition to a possible extra 100 acres in Costa Rica could produce $15 million worth of moringa every year. Between the land the company’s already got plus the other land the company is looking to add, we can reasonably say we’re talking about annual sales in the teens to maybe into the 20’s of millions of dollars. And just last week, New Global Energy announced it was pairing up with the world’s largest moringa farm – in Leon, Nicaragua – to bring a whole new brand of moringa products to the market. The brand name will be Moringa Reserve, LLC, and it’s being established specifically by NGEY for the purpose of turning the farm’s massive 180-acre moringa supply into moringa-based products for U.S. consumers.

The other aspect of NGEY is its tilapia farm, which just began breeding season. New Global Energy is starting out with a record number of fish which should lead to a record-breaking a amount of tilapia production, which in turn means a record-breaking level of tilapia revenue.

Last week’s press release specifically said:

‘At Aqua Farming Tech, NGE’s wholly owned subsidiary, there are two spawning seasons in the Spring and Fall that produce one million tilapia each that we expect to be a total of two million annually. This month, the Fall season’s tilapia are coming to full maturity at approximately one pound each and are preparing to go to market at $3.60 per pound (delivered) or $3.00 per pound (picked up at the farm) with price increases expected.’

Crunching the numbers, this translates into annualized revenue of somewhere between $6 million and $7.2 million. What the press release didn’t say…

Investors and consumers would actually need to go back to Tuesday’s letter to shareholders to glean it,but New Global Energy’s tilapia is in the process of becoming a “Certified Organic” food, which will allow the company to market its fish as organic in addition to being non-GMO… a real marketing tool in the modern world of informed and concerned consumers. Non-GMO tilapia is selling for between $12 and $14 a pound in some markets, and the certification will open up a wide number of venues to which NGEY can serve as a supplier.

The point, however, is that NGEY is a real business driving real revenue with real product in hand selling to a real market. Cannabis Sativa is none of those things.

That’s not to say Cannabis Sativa and other penny stocks in and out of the marijuana space can’t someday justify their lofty valuations. It is to say though, from a risk-vs-reward perspective right now, NGEY has more to offer.

For more on New Global Energy, visit the company website here

 

Source: Small cap network

 

 

Source: Small Cap Network

3D printing, or additive manufacturing, is an exciting and dynamic sector. 3D printing has the ability to change the way products are developed, manufactured, purchased and acquired. Currently there are a variety of stocks that focus on 3D printing. For the investor seeking penny stocks in the 3D printing sector, there are fewer choices. 3D printing-related penny stocks include Tinkerine and Sigma Labs, Inc. Penny stocks present many risks, but for the investor looking for more speculative investments they can also provide attractive upside potential. (To learn more about penny stocks in general, see The Lowdown on Penny Stocks.)

Tinkerine
Tinkerine (TKSTF) is based in Canada and trades on the over-the-counter (OTC) market. The firm is focused on the consumer and educational 3D printing market and sells its Ditto Pro 3D printer, software, filament, and accessories. The Ditto Pro 3D printer has garnered favorable reviews particularly from Make: magazine and received the best 3D printing product award at CES Asia.

Tinkerine’s second quarter of 2015 results show strong revenue growth with Q2 2015 revenue being more than triple first quarter 2015 revenue, growing from C$108,000 to C$345,000. (Tinkerine’s financial results are presented in Canadian dollars). Second quarter revenue also was more than six times greater than the posted second quarter 2014 revenue of C$54,603. Despite the strong revenue growth, the firm continues to operate at a loss. In the 2015 second quarter, Tinkerine recorded a loss of C$340,076, but it is trending in a positive direction. The four quarters prior to Q2 2015 all had losses greater than C$500,000.

Read more: Two Penny 3D Printing Stocks To Watch Out For (TKSTF, SGLB) | Investopedia http://www.investopedia.com/articles/investing/091615/two-penny-3d-printing-stocks-watch-out.asp#ixzz430XhMaaT
Follow us: Investopedia on Facebook